Alvotech announces record preliminary results for revenues and ebitda for the second quarter of 2024

Alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced certain preliminary, unaudited key financial information for the second quarter and six months ended june 30, 2024, as follows:
ALVO Ratings Summary
ALVO Quant Ranking